ClinicaliQ Trial Snapshot
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) — Active Not Recruiting • Phase III • Oncology • NCT06109779.
- Adding rilvegostomig to standard chemotherapy after biliary tract cancer surgery may improve outcomes compared to chemotherapy alone.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent. Conditions: Biliary Tract Cancer Interventions: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil] Lead Sponsor: AstraZeneca Planned Enrollment: 760 participants